Podcasts about NMS

Volební preference českých politických stran se po mnoha měsících, kdy jejich pročítání bylo spíše nudné, trochu zajímavěji pohnuly – poprvé od voleb v loňském roce by alespoň podle průzkumu agentury NMS pro Novinky získala ve sněmovně těsnou většinu současná opozice. Na tom má podíl především pokles Motoristů sobě pod pět procent, na 4,4 procenta, velice mírně, v rámci statistické chyby, ztratila i hnutí ANO a SPD.Všechny díly podcastu Názory a argumenty můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Poslaneckou sněmovnu by podle volebního modelu agentury NMS ovládla opozice – zejména proto, že by se do dolní komory nedostali Motoristé sobě. „Jsou na hraně, vzhledem ke statistické chybě mohou být klidně přes pět procent. Ale důležitá zpráva pro ně je, že za dva roky relevantní existence nerostou. Přijde mi, že ta strana nemá ambice, a pokud ano, tak je dobře skrývá,“ hodnotí v Interview Plus komentátor serveru Seznam Zprávy Jindřich Šídlo.Všechny díly podcastu Interview Plus můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

We talk about a fun, top-tier game for Star Wars fans plus a chat about Squadron 42 delays and still no NMS news. That and more on this episode of the New Overlords Podcast with Sema and @MaxTheGrey. MP3 Direct Download Link YouTube Link Catch us in Discord at http://newoverlords.com/discord for notes on when we … Zero to hero – New Overlords Podcast 622: Star Wars Zero Company Read More » The post Zero to hero – New Overlords Podcast 622: Star Wars Zero Company first appeared on NEW OVERLORDS.

Danes, 31. avgusta 2026 so v Narodnem muzeju Slovenije predstavili začetek javnega spletnega dostopa do predmetov, ki jih hrani 29 bodisi državnih ali lokalnih muzejev s statusom javne muzejske službe. Register premične kulturne dediščine oziroma premična e-dediščina je bil še edini manjkajoči del celovite sodobne javne politike njenega ohranjanja in predvsem javne dostopnosti s pomočjo interneta. Skupaj z resornim ministrstvom je projekt Premična e-Dediščina 2023-2025 koordinirala Služba za premično dediščino in muzeje v okviru NMS. Z njenim vodjo, kustosom Juretom Kusetičem in dokumentalistko kustosinjo Nino Sotelšek smo v pogovoru povzeli temeljne obrise in izhodiščno stanje spletnega dostopa do premične kulturne dediščine. Naslov premične e-dediščine: https://rpkd.nms.si/ FOTO: Z leve Nina Sotelšek in Jure Kusetič VIR: Program Ars, G.Tenze

Podľa najnovšieho modelu agentúry IPSOS pre Denník N drží Progresívne Slovensko tesný náskok so ziskom 18,1 % pred druhým Smerom, ktorý má 17,9 %. Agentúra NMS zasa namerala PS 19,2 % a Smeru 16,5 %. Štátny Infostat však poradie otočil a víťazom by sa podľa neho stal Smer s 20,3 % pred PS s 18,7 %.Nejde pritom len o štatistický šum. Vážený Volebný barometer Aktuality.sk ukazuje, že PS postupne stratilo svoje maximá a ich skalné jadro sa zmenšilo z 13 na 9 percent. Naopak, Igor Matovič chytá druhý dych s 26-percentnou dôverou u najmladších voličov a Hlas v meraniach NMS padá na dno k 5,9 percenta.V najnovšom vydaní podcastu Aktuality.sk sa s analytikom a sociológom agentúry IPSOS Romanom Pudmarčíkom pozrieme na to, kam sa strácajú voliči lídrov, čo robí s náladami spájanie strán a či nás po ďalších voľbách čaká pat.

Podľa najnovšieho modelu agentúry IPSOS pre Denník N drží Progresívne Slovensko tesný náskok so ziskom 18,1 % pred druhým Smerom, ktorý má 17,9 %. Agentúra NMS zasa namerala PS 19,2 % a Smeru 16,5 %. Štátny Infostat však poradie otočil a víťazom by sa podľa neho stal Smer s 20,3 % pred PS s 18,7 %.Nejde pritom len o štatistický šum. Vážený Volebný barometer Aktuality.sk ukazuje, že PS postupne stratilo svoje maximá a ich skalné jadro sa zmenšilo z 13 na 9 percent. Naopak, Igor Matovič chytá druhý dych s 26-percentnou dôverou u najmladších voličov a Hlas v meraniach NMS padá na dno k 5,9 percenta.V najnovšom vydaní podcastu Aktuality.sk sa s analytikom a sociológom agentúry IPSOS Romanom Pudmarčíkom pozrieme na to, kam sa strácajú voliči lídrov, čo robí s náladami spájanie strán a či nás po ďalších voľbách čaká pat.

Good stuff coming soon including speculation on the next NMS update. Then Sema has played a ton of this week’s WoW update so we dive in. That and more on this episode of the New Overlords Podcast with Sema and @MaxTheGrey. MP3 Direct Download Link YouTube Link Catch us in Discord at http://newoverlords.com/discord for notes … Xal'atath is on vacation – New Overlords Podcast 619: WoW 12.1 Read More » The post Xal'atath is on vacation – New Overlords Podcast 619: WoW 12.1 first appeared on NEW OVERLORDS.

Kdo je nejvýraznějším lídrem opozice v Česku? Průzkum agentury NMS pro Novinky.cz přinesl výsledky, ze kterých by měl jistě radost Jára Cimrman. Na prvním místě se umístil prezident Petr Pavel, na druhém premiér Andrej Babiš. Ani jeden přitom k opozici nepatří. Dalo by se tedy říci, že jde o první aut v dějinách průzkumů veřejného mínění. Zkusme to ale vzít vážně. O čem výsledky svědčí?Všechny díly podcastu Názory a argumenty můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Mittlerweile werden in NMS einige Maßnahmen vor den Schulen vorgenommen, um die Schulwege-Sicherheit zu erhöhen. Doch reicht es, nur dort etwas zu ändern? Dazu gab es einen Schulwege-Check an der Grundschule an der Schwale, den der Verkehrsclub Deutschland, Ortsgruppe NMS durchgeführt hat. Außerdem setzen wir die Radtour „Klimaanpassung erfahren“ fort, die am 15. Juni 2026 von der Stabsstelle Klima und Umweltqualität der Stadt Neumünster organisiert wurde. Wir sind am Kleinflecken und in der Schwaleniederung am Tivoli. Das Umweltmagazin am Montag um 19 Uhr. In einer Extraausgabe des Umweltmagazins am Montag um 21 Uhr erfahren wir im Rahmen der Veranstaltungsreihe „Fokus Wärme“ etwas zum Themenkomplex „Wärme & Strom gemeinsam nutzen“.

Near, far, wherever you are, I believe the airship soars on."A Link between hairstyles" by Angelica FreyDiscussed: Three Houses at SGDQ, Rhythm Heaven Groove, the last Switch 1 game, potential future of Rhythm Heaven, Nintendo's surprise updates, an exciting announcement, FFIX, the horrors of Tetra Master, daydreaming about FFXIV on Switch, if JaVert was funny, Shovel Knight Dig, various eras of roguelikes, No Man's Sky, multiplayer in NMS, survival games, Big Bang Betty, Fields of Mistrial 1.0 on the horizon Find us everywhere: https://intothecast.onlineBuy some merch, if you'd like: https://shop.intothecast.onlineJoin the Patreon: https://www.patreon.com/intothecast---Follow Stephen Hilger: https://bsky.app/profile/stephenhilger.bsky.socialFollow Brendon Bigley: https://bsky.app/profile/bb.wavelengths.onlineProduced by AJ Fillari: https://bsky.app/profile/ajfillari.bsky.social---Season 8 cover art by Scout Wilkinson: https://scoutwilkinson.myportfolio.com/Theme song by Will LaPorte: https://ghostdown.online/---Timecodes:(00:00) - Intro (00:38) - It's SGDQ! (01:35) - Rhythm Heaven Groove | A game on the original Nintendo Switch (20:27) - An exciting announcement! (27:50) - Thank you so much for your support!!!!! (29:25) - Break (29:26) - Final Fantasy IX |

“Sme svedkami hlbokej nedôvery voči elitám štátu”, hovorí Michal Mislovič z agentúry NMS.Pätnásť ministrov, dvanásť trojkárov, traja štvorkári. V čase, keď prichádzajú domov s koncoročnými vysvedčeniami žiaci a študenti, tie svoje dostali aj ministri štvrtej vlády Roberta Fica. Ich známkovanie namerala prieskumná agentúra NMS v reprezentatívnom prieskume na vyše tisícovej vzorke. Účastníci prieskumu dostali príležitosť oznámkovať jednotlivých členov vlády rovnako, ako sa známkuje v škole – od jednotky po päťku. Ani jeden minister pritom nezískal priemernú známku lepšiu ako je trojka. Na čele ministerského známkovania sú ministri Ráž-Tomáš-Taraba, na chvoste Šimkovičová-Migaľ a Huliak. Najviac však pri hodnotení rozdeľoval názor na ministra obrany Roberta Kaliňáka. Na prieskum sa pozrieme s Michalom Mislovičom z agentúry NMS. Všimneme si tiež vývoj preferencií a postoje ľudí k blížiacemu sa referendu.

“Sme svedkami hlbokej nedôvery voči elitám štátu”, hovorí Michal Mislovič z agentúry NMS.Pätnásť ministrov, dvanásť trojkárov, traja štvorkári. V čase, keď prichádzajú domov s koncoročnými vysvedčeniami žiaci a študenti, tie svoje dostali aj ministri štvrtej vlády Roberta Fica. Ich známkovanie namerala prieskumná agentúra NMS v reprezentatívnom prieskume na vyše tisícovej vzorke. Účastníci prieskumu dostali príležitosť oznámkovať jednotlivých členov vlády rovnako, ako sa známkuje v škole – od jednotky po päťku. Ani jeden minister pritom nezískal priemernú známku lepšiu ako je trojka. Na čele ministerského známkovania sú ministri Ráž-Tomáš-Taraba, na chvoste Šimkovičová-Migaľ a Huliak. Najviac však pri hodnotení rozdeľoval názor na ministra obrany Roberta Kaliňáka. Na prieskum sa pozrieme s Michalom Mislovičom z agentúry NMS. Všimneme si tiež vývoj preferencií a postoje ľudí k blížiacemu sa referendu.

I got out late today. Waited for the rain to move off. Talked about NMS and the Walker and Cooper book Dawn of Mankind. Among other things.

Slept in. Beautiful night’s sleep for a change but up-shot is that I didn’t get going early this morning. It’s already coming up on “broiling” season. Talked about yesterday’s bread, why NMS turning into a grind is a good thing, … Continue reading →

SWTOR 7.9 is here with a story conclusion, 007 First Light is really good, and the NMS expedition is still in progress. That and more on this episode of the New Overlords Podcast with Sema and @MaxTheGrey. MP3 Direct Download Link YouTube Link Catch us in Discord at http://newoverlords.com/discord for notes on when we record … Better than Goldeneye? – New Overlords Podcast 609: 007 First Light Read More » The post Better than Goldeneye? – New Overlords Podcast 609: 007 First Light first appeared on NEW OVERLORDS.

NMS has been divided into 3 teams in order to battle the Hive Of Glass. Fight the swarms and collect the ichor. Who will be the champions of the Universe.

Už piaty rok po sebe naša krajina čelila poklesu obyvateľov. Aktuálne sa pôrodnosť dostala na také historické minimum, ktorého úroveň bola ešte horšia ako počas Druhej svetovej vojny. Slovensko vymiera. Rodí sa stále menej a menej detí, žijeme dlhšie ako v minulosti a tak sa veková štruktúra našej spoločnosti zásadne mení - a zásadné budú i dôsledky. Napriek tak obľúbeným, neustále opakovaným a hlasným deklaráciám o dôležitosti rodiny, či o deťoch ako priorite spoločnosti, však žiadne vlády za ostatné 2-3 dekády nedokázali dať účinné a ani funkčné odpovede ako negatívny demografický trend zvrátiť a uistiť mladých ľudí, že byť rodičom a založiť si rodinu je nielen dobrým, ale aj bezpečným riešením vlastnej budúcnosti. Kočíkovné, krúžkovné či všakovaké rodičovské bonusy zjavne nezaberajú, otázkou preto je, či vôbec poznáme skutočné dôvody, prečo sa mladí ľudia obávajú zakladať rodiny, byť rodičmi a privádzať do tohto sveta svoje vlastné deti. Jednou z odpovedí môže byť aj Veľký prieskum rodín, ktorý pre finančný dom UNIQUA pripravila agentúra NMS Market Research. Podľa neho pocit bezpečia v našich rodinách opäť klesol pričom naše rodiny najviac trápia finančné starosti, ale aj obavy z budúcnosti či zdravotné problémy. Čoho sa mladí ľudia tak veľmi obávajú, ako sa s tým dá popasovať a čo skutočne trápi naše rodiny, sú to len obvyklé peniaze alebo je to i obava z budúcnosti či dokonca z členov vlastnej rodiny? Ráno Nahlas, s Michalom Mislovičom z agentúry NMS. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Už piaty rok po sebe naša krajina čelila poklesu obyvateľov. Aktuálne sa pôrodnosť dostala na také historické minimum, ktorého úroveň bola ešte horšia ako počas Druhej svetovej vojny. Slovensko vymiera. Rodí sa stále menej a menej detí, žijeme dlhšie ako v minulosti a tak sa veková štruktúra našej spoločnosti zásadne mení - a zásadné budú i dôsledky. Napriek tak obľúbeným, neustále opakovaným a hlasným deklaráciám o dôležitosti rodiny, či o deťoch ako priorite spoločnosti, však žiadne vlády za ostatné 2-3 dekády nedokázali dať účinné a ani funkčné odpovede ako negatívny demografický trend zvrátiť a uistiť mladých ľudí, že byť rodičom a založiť si rodinu je nielen dobrým, ale aj bezpečným riešením vlastnej budúcnosti. Kočíkovné, krúžkovné či všakovaké rodičovské bonusy zjavne nezaberajú, otázkou preto je, či vôbec poznáme skutočné dôvody, prečo sa mladí ľudia obávajú zakladať rodiny, byť rodičmi a privádzať do tohto sveta svoje vlastné deti. Jednou z odpovedí môže byť aj Veľký prieskum rodín, ktorý pre finančný dom UNIQUA pripravila agentúra NMS Market Research. Podľa neho pocit bezpečia v našich rodinách opäť klesol pričom naše rodiny najviac trápia finančné starosti, ale aj obavy z budúcnosti či zdravotné problémy. Čoho sa mladí ľudia tak veľmi obávajú, ako sa s tým dá popasovať a čo skutočne trápi naše rodiny, sú to len obvyklé peniaze alebo je to i obava z budúcnosti či dokonca z členov vlastnej rodiny? Ráno Nahlas, s Michalom Mislovičom z agentúry NMS. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Podle květnového volebního průzkum agentury NMS by volby do Sněmovny vyhrálo ANO s 32,5 % hlasů. ODS a STAN by volilo mezi 14–15 % voličů. Do Sněmovny by se dostali ještě SPD a Piráti. Těsně pod pětiprocentní hranicí nutnou pro vstup do Sněmovny se nacházejí Motoristé sobě. „To, že vznikl nový projekt, jako je Naše Česko, zatím s ničím moc nehýbe,“ konstatuje Jakub Bakule. V pořadu Jak to vidí… dále představuje velké šetření týkající se rodinných vazeb v Česku a na Slovensku.Všechny díly podcastu Jak to vidí... můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Advances in immunotherapies for multiple sclerosis and related disorders have increased the risk of infections and raised important questions about vaccination efficacy. This episode reviews infection risks across treatment classes, emphasizes the importance of monitoring and patient education, and discusses optimal vaccine timing to preserve protective immune responses. In this episode, Aaron L. Berkowitz, MD, PhD, FAAN, speaks with Avindra Nath, MBBS, FAAN, coauthor of the article "Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Dr. Nath is the chief of the Section of Infections of the Nervous System at the National Institute of Neurological Disorders and Stroke, National Institutes of Health, in Bethesda, Maryland Additional Resources Read the article: Infection Risk and Vaccine Considerations in Multiple Sclerosis and Related Disorders Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Full episode transcript available here Dr Berkowitz: Over the last decades, there has been a revolution in the treatment of multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic conditions with countless new, highly effective medications. However, with every new treatment comes new risks; and in the case of immunomodulatory therapy, many of those risks relate to infection. Today, I have the privilege of talking with an expert on this topic, Dr Avindra Nath, about the infectious risks of treatments for multiple sclerosis and other immune-mediated neurologic disorders.  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Berkowitz: This is Dr Aaron Berkowitz, and today I'm interviewing Dr Avi Nath about his article on vaccine considerations and infection risk in multiple sclerosis and related disorders, which he coauthored with Dr Amit Bar-Or. This article appears in the April 2026 Continuum issue on multiple sclerosis. Welcome to the podcast, Dr Nath, and could you please introduce yourself to our audience?  Dr Nath: Thanks very much for inviting me to this podcast. I'm absolutely delighted to have the opportunity to discuss our areas of interest and expertise related to infections and vaccinations for MS patients. My area has been studying the infections of the nervous system since the beginning of the AIDS pandemic, and over the years and decades, we've developed expertise related to various types of CNS infections. That includes ones that are developing in individuals who have immune compromise due to a variety of different reasons. Dr Berkowitz: Fantastic. Well, glad to have the opportunity to speak with you today. When I was in medical school---and you were my attending, actually, we were just reminiscing, which we probably think was not that long ago, but is now over twenty years ago---there were just two medications for MS, right? Beta interferon and glatiramer acetate. And now we have over a dozen, and it's amazing to think of all the progress in these last two decades, as well as for related diseases like NMO. I don't think we even had the aquaporin-four biomarker, right, when I was working with you as a med student in the early 2000s. Dr Nath: And that certainly dates me a lot.  Dr Berkowitz: Both of us.  Dr Nath: Yeah.  Dr Berkowitz: Of course, with all these new treatments, these have been amazing advances for our patients, right? But these come with new treatment-related risks to monitor for with the immunomodulatory medications for MS and related disorders. And one of those most important risks is that of infection. So, your article reviews the potential infectious complications of medications used to treat MS, NMO, etc, and also covers considerations related to thinking about vaccines in this patient population. So, as the MS treatment landscape grows, I can say as a general neurologist, keeping up with all these medications and what to screen for and what to worry about and when to vaccinate just becomes more challenging every year. And your article has so many helpful tables, some organized by medicine, some organized by- sorry, medication, some organized by infection, some by vaccines. So, this is gonna be a great resource for our providers to print out and tape up in their clinic rooms. We won't be able to get into all the depth and detail that you have in this article today, but I do want to focus on some of the key points here related to the common medications we use for MS and which infections to think about and which vaccine considerations we might need to keep in mind for these medications. But before we delve into the drugs, I just wanna ask you more broadly, you talk in the article about the challenge of patients with immune-mediated diseases who are on immunomodulatory therapy being at risk for both flares of their disease and for infections; and these infections can present somewhat atypically, right, in immunomodulated hosts, to maybe coin a term you can correct me on, because they can't mount the full inflammatory response. So how do you approach new symptoms in patients on these immunomodulatory medicines as far as distinguishing disease flare from a treatment-related infection?  Dr Nath: So, I have to say that although a lot of new treatments have come along for MS, and they've really, you know, improved the outcome tremendously and there are so many different options, it has also kept people like me relevant because they cause a lot of various types of infections, and so keeps me in business all the same. But just as you mentioned, there's so many of them, even I have difficulty keeping track of what does what. So, you do need to be able to refer back to published literature, and the tables, I hope, will be quite useful in that regard. You're absolutely right, and you can get new infections, you can get reactivation of existing infections, and you can get atypical presentations of various types of infections that you may not normally think of. So that presents multiple challenges to the treating physician. The other interesting thing about MS is, just as you mentioned, that you already have CNS lesions to begin with. Now, on top of it, you have an infection, so now how to sort out what is the existing disease and what is the infection, it can again become challenging. But one thing is for sure: all these infections are caused by an organism. So, what you really need to do is, the underlying diagnostic is to demonstrate the presence of the organism. Whether you demonstrate it depending on the infection in the spinal fluid or in the brain or, you know, some peripheral organ system, that is going to be key to making the diagnosis. So, all your clinical acumen is good, but that alone may not be sufficient. Dr Berkowitz: Very good. So, when you see a, a patient now who has a new neurologic symptom in the context of an immune-mediated disease who's on immunomodulatory therapy, what goes through your mind? Are you thinking this disease and this drug, and sort of what are the infections, and does the syndrome match? Or are you thinking, you know, you can't always rely on the imaging to distinguish between, say, a flare of an MS and PML because white matter lesions could look similar? How do you sort of approach this scenario when it comes up?  Dr Nath: So, you're right. You have to keep an open mind so that even though you know some infections are more likely to occur with certain types of medications, that doesn't mean that others cannot occur. So, I think when you first see the patient, you should not jump to conclusions, but rather have an open mind. But yes, for example, your patient is on natalizumab, the chances of PML are going to be high. It's a very interesting drug. It does not cause immune compromise in the periphery, but what it's doing is preventing these cells from getting into the brain. So, because then it's acting at the blood-brain barrier. So that means that organisms that are already present in the brain have an opportunity to get reactivated. Turns out you don't have a lot of organisms in the brain, except JC virus seems to be one of them that does somehow, in some individuals, manage to reside out there. And so that can get reactivated. It can get reactivated in the periphery and then enter the brain, too. So, where the very specific mutations have to occur in that virus in order to take residence in the brain. That would be a suspicion that you might have, and MRI can be useful in, again, helping you think about that possibility. If you have typical lesions involving the U fibers, they're demyelinating, usually you do not have much edema around them because patient is immune compromised, but certainly within the brain in these individuals. And so, then you need to demonstrate the organism. The demonstration of the organism should be in the spinal fluid and not in the blood because in the virus, it can-- is reservoir in the kidneys and in the lymph nodes, and periodically it'll shed into the blood. Detection of the organism in the blood can be a false positive, but in the spinal fluid, it shouldn't be there unless you have an infection. Or if you cause a traumatic tap, I guess, if a patient is viremic, that's a possibility, but those are extremely rare. So at least for PML, that's the way that you would diagnose it. Now, you can develop, for example, if an individual is on fingolimod, you can get a wide variety of infections. Here it's a totally different type of mechanism of action. Here the cells are trapped within the lymph nodes, so that means now your entire periphery is immune compromised, right?  So here you can get viral infections, bacterial infections, fungal infections. So here, if a patient presents with new neurological symptoms, you have to have a really open mind for all these possibilities. Now, let's say a patient was on dimethyl fumarate, and dimethyl fumarate causes neutropenia early on. So here you have to worry about an individual developing bacterial infections, so latent tuberculosis or bacterial meningitis can occur in these individuals. That's something to keep in mind. It's not that other infections cannot occur with dimethyl fumarate, you can see PML and other things too, but the chances of bacterial infections are greater. So, you got to make sure that you draw all the cultures for that purpose. Similarly, if you're on a complement inhibitor, like a C5 inhibitor or the thing that I could use in NMO, there are the chances of meningococcal meningitis. So, these patients, you need to prevaccinate them before you start these kinds of treatments and look for that possibility. When you suspect bacterial infections, particularly acute bacterial meningitis, there time is of essence. Also, in some of the acute viral infections, for example---herpes encephalitis is another one---you have to be so careful, and if you suspect any of them, even if they're with possibly atypical manifestations, you treat first and then diagnose later, and draw all your cultures, whatever you need to, and just treat them. And these infections can also cause cerebral edema, so one has to be careful about doing spinal taps in these individuals. You want some kind of neuroimaging before you do them. In the days when we didn't have neuroimaging, we used to say, "Okay, if your patient has focal neurological signs or is comatose, you don't do it." But these days, you can get imaging very quickly and very easily. All the-- Because of our stroke management, we've learned how to do them so quickly. So, I think there's little excuse not to do imaging and prevent herniation from occurring.  Dr Berkowitz: That's very helpful. So, using the information we know about the drug, and we're going to rapid-fire review some of that in a bit to know what infections the patient is susceptible to, but acknowledging that any patient can get any infection, right? Whether they're on particular medications or not. And then if you're not sure, based on the neuroimaging, which as you said, is helpful, but not always helpful in distinguishing between infections and flares or, as you said, in the case of meningitis, encephalitis, early on at least, especially in immunocompromised or immunomodulated, quote unquote, patient might not see the typical imaging. So really, when safe, getting CSF or cultures, PCRs, and other infectious studies too is really gonna be the definitive diagnostic maneuver here. Is that fair summary across the board?  Dr Nath: I think you said that absolutely right. And you summarized that correctly. And, you know, thing about infection, a lot of neurological diseases are, you know, diagnosed by clinical acumen, like your Parkinson's and Alzheimer's and others. Think about infections is caused by an organism, demonstrate the organism, right? That should be your goal. It doesn't mean that clinical acumen is not important, but here you have an opportunity to demonstrate the organism, so you should depend upon that.  Dr Berkowitz: Okay. Well, you gave us a nice segue by talking about some of the infections to worry about with some of the medications. So what I'd like to do now for the sort of second half of our interview here is to go through some of the more common medications used for MS, and if we have time, for NMO, and just sort of go kind of rapid fire here, and for each medication, if you can tell us the kind of top infectious concerns and whether when to consider them or what screening needs to take place before or during administration of the medication, and then any vaccine considerations we should be aware of. Some of these will obviously be quite short depending on the medicine. So, going back to the two medications I alluded to earlier that were the only ones in play when you and I last saw each other on the wards when I was a medical student, beta interferon, glatiramer acetate, any infections or vaccine considerations with these medications?  Dr Nath: No, I think they're probably your safest medications now as far as immunomodulatory therapies are concerned. These two, and IVIG, if you ever use them, are probably the safest, do not require any vaccine considerations, per se. Dr Berkowitz: Perfect. Okay. So, moving on to fingolimod and others in the sphingosine-one phosphate receptor modulator family, what are the infectious considerations? Any prescreening or vaccination considerations?  Dr Nath: I think all your patients should be prescreened for antibodies to JC virus, because there is a risk for PML, and those who are positive should be closely monitored. So, it's not an absolute contraindication for using these medications, but they just require closer monitoring. With this class of drugs, PML is of consideration. Also, these varicella-zoster virus infection, yeah, with that you can develop zoster encephalitis or myelitis. It can present with motor symptoms as well, which can be atypical. You don't usually see them otherwise in immune-competent individuals. So, varicella-zoster, sometimes you can develop encephalitis, also vasculitis with varicella-zoster, so one has to be careful. So, getting the shingles vaccine can be actually very helpful to prevent these things. And then some patients can even develop herpes simplex encephalitis also, and that can be extremely atypical. So, they don't- they can involve the basal ganglia, can involve the brain stem and cerebellum. So again, your index of suspicion should be very high. Interestingly, although HSV encephalitis has been associated with NMDA receptor encephalitis, those reports of NMDA receptor encephalitis have not been published yet with NMS patients. Not sure why, maybe they just have been missed. But that doesn't seem to be a major concern. And then there are a whole host of other infections that can occur with this class of drugs, and that can include toxo; fungal infections, particularly crypto. There's a case report of histoplasmosis; hepatitis virus, particularly hepatitis C; and then the poxvirus is a good example. You can get molluscum contagiosum; warts with papillomavirus; you can get atypical mycobacteria; and even Kaposi sarcoma, which is HHV8. So, there's a huge variety of infections with the sphingosine one phosphate receptor modulators.  Dr Berkowitz: And any- aside from screening for JC virus before initiating these, any- and then continuing to monitor for JC antibody index, any other considerations as far as labs to send, monitoring before or on the drug or vaccine considerations for patients on fingolimod and the others in this category, siponimod, etcetera?  Dr Nath: Yeah, there are a lot of things to consider. All the details are really available in the chapter if you look at them. But briefly, all the things that one could potentially vaccinate patients for, all these infections I mentioned, one should do so. The timing is critical so that if you can do it before treatment, I think, before starting treatment, that is absolutely important. And you got to give them at least, you know, two to three weeks for these vaccines to take effect before starting your medication. If your patient already arrives on a medication, then you got to play this game of you know, before the next dose, give them again two to three weeks before the next dose and start vaccinating them and get all the vaccines in. Broadly, about the things to worry about the vaccines are you have live vaccines, and you've got the inactivated vaccines or the subunit vaccines. You have to be careful with live vaccines, because if your patient is immunocompromised, that virus can sometimes itself cause harm. For example, you know, yellow fever is one, and there you can develop encephalitis from it. Measles, mumps, rubella, these are all live vaccines. Now, the good thing is that a lot of us have been immunized very early in childhood, but that may not be the case any longer. And so, these things, one has to be very careful with when you're giving live vaccines, that we want to avoid them as much as possible, and individuals are gonna be immune-compromised. But all the others, meningococcus, for example, you should- the HPV vaccines, the varicella zoster vaccines, all these things, you've got to pre-vaccinate and make sure that they have an antibody response to them before starting immunocompromising therapy. Dr Berkowitz: Perfect. Okay, moving on to some of the other orals. What infectious and/or vaccine considerations do we have with teriflunomide?  Dr Nath: Okay, yeah. Teriflunomide is a very interesting drug. It's relatively safe. There is concern about the possibility of varicella zoster infection, people have reported that, and also tuberculosis. But PML is extremely rare, if not at all, and we haven't seen herpes encephalitis quite yet.  Dr Berkowitz: Got it. How about dimethyl fumarate? Dr Nath: Yeah. So dimethyl fumarate is... as I mentioned earlier, it's interesting because it causes this neutropenia. It's transient, but it occurs early on, and these patients can be at risk of PML, although small. They can develop varicella zoster virus infection, herpes encephalitis, and also fungal infections. For example, cryptococcal infection has been reported with dimethyl fumarate. Dr Berkowitz: Okay. We've spoken a bit about natalizumab and PML, and you have extensive information on this in your article, and I'll defer the reader to that. But for natalizumab, what are the key points every neurologist should know about natalizumab and PML as far as from the practical perspective, screening, frequency of screening, when to worry, when to not use natalizumab at all in the first place based on what you find in your screening for JC virus? What are the key points every neurologist should know?  Dr Nath: Uh, yes. You bring up an important point, and that is all patients should be monitored for JC virus. If they're JC virus-negative, so that's your most ideal patient to go on natalizumab, but that doesn't mean they cannot get infected with the virus. In fact, there's an interesting study claiming that, you know, patients, when they get these infusions, they're all sitting in the same room getting infused. Some have JC virus, some don't have JC virus, and so there's the potential that we may be aiding the transmission here in some way or another. The virus is an interesting one. It comes out in urine, and then it's spread through oral contamination, gets into the tonsils, and then spreads from there to your marrow and resides in the kidney and the marrow, as well as the lymph nodes, forever. So, you, you have to monitor these patients to see that during the course, even if they're negative, they could turn out positive. So, every six months or a year, an antibody test should be done on all patients irrespective. If a patient already has antibodies, that's not an absolute contraindication. It just means you've got to monitor them closely for development of new symptoms, and if, whenever there are new symptoms, don't just assume this is due to MS, but just make sure the MRI is done with and without contrast. The- and if there's still a suspicion, that you do a CSF evaluation for JC virus. Just detecting, looking for JC virus in the blood, a rising titer is another thing that can help you. And so, the titer is also important. And the reason you have rising titers is it means that there's an infection that's already occurred in the brain, and the immune system is reacting to that infection by increasing titers. But that alone is not sufficient to make the diagnosis. You still- that gives you an index of suspicion. You've got to then do the MRI and the spinal tap to, you know, be absolutely certain. So, each patient is a little bit different, so the way you monitor them is going to depend on where they are. You know, if they've had prior immunomodulatory therapy before starting natalizumab, or if they're on natalizumab for more than two years, then the chances of PML are much greater, so you may want to monitor them more closely. Uh, they never had any prior immunomodulatory therapy, you're just starting natalizumab, maybe once a year is sufficient. So, I think you've got to tailor it depending on what your risks are for each patient. Dr Berkowitz: Perfect. That's very helpful. And again, you write extensively about PML and natalizumab and PML considerations in your article. So, for a more detailed and in-depth discussion of what we just discussed, definitely hope readers will take a look at your article. Okay. Last but not least---certainly not least, 'cause we're using these probably, it seems, the most commonly in many places I've worked---rituximab, ocrelizumab are B-cell therapies for MS. What are some of the infectious and vaccine considerations related to these infusion medications?  Dr Nath: So, there's concern for PML with anti-B-cell therapies also, maybe not to the same degree as natalizumab, but the same principles should be applied. A lot of people think that these are relatively safe. I don't think so. I think we see enough number of patients on B-cell therapies with PML. So, I would use the same caution because these infections are... you know, can be fatal. So, one should be very careful, even with anti-B-cell therapies. And just with natalizumab, you also have the risk of VZV infection causing shingles. HSV1 has been reported, but there's another interesting complication that has been reported with anti-B-cell therapies, and that is severe West Nile encephalitis. And as mosquitoes-borne diseases are getting more and more prevalent, and we're seeing West Nile cases erupting every summer, I think one's got to be, you know, very cognizant of the fact that this can occur. These patients should take precautions to prevent mosquito bites from occurring and not expose themselves to areas where they could be at risk for it. Unfortunately, there is no vaccine for it and no specific treatment for West Nile. So, all one can do is use prevention strategies for mosquito bites.  Dr Berkowitz: Yeah, I'm glad you mentioned that. I think the only really truly severe neuroinvasive cases I've seen of West Nile virus have indeed been in patients who were being treated with B-cell therapy. Not, if I'm remembering correctly, for immune-mediated disease, but for a lymphoma, so probably other confounding factors there. But yeah, it's a disease we learn about and think about, but I've only seen the most severe cases in patients who had abnormal immune systems, so I'm glad you flagged that. This has been a very helpful discussion, and I've learned a lot from you. I learned a lot from your article, just as I did when you were my attending some 20-something years ago on the wards when I was a medical student. So, it's good to continue learning from you through your writing and research, and today from getting to talk to you again. I encourage our readers to read your article and to bookmark those tables for when these considerations come up for your patients on these immunomodulatory therapies and you're wondering which infections to worry about and how to manage vaccines in this patient population. So again, today I've been interviewing Dr. Avi Nath about his article on vaccine considerations and infection risk in multiple sclerosis and related disorders, which he wrote with Dr. Amit Bar-Or. This article appears in the April 2026 Continuum issue on multiple sclerosis. Be sure to check out Continuum Audio episodes from this and other issues, and thank you again to our listeners for joining today.  Dr Nath: Thank you so much, Aaron, for that wonderful interview, and I'm extremely proud of all your accomplishments over the last 20 years. You've done an amazing job, and it was such a pleasure to see you and to be able to do this interview with you. Thank you again.  Dr Berkowitz: Thanks. That means a lot. I never would have imagined- we won't say 20, how many, but 20-something years ago as the medical student looking up to you and all your expertise on these infections and all of your research that led to so much of our understanding on these, that I would find myself interviewing you two decades later. So, for all the students listening, you never know where you'll end up, but I appreciate your very kind words.  Dr Nath: That's what we hope for all our students. Thank you so much.  Dr Berkowitz: Thanks again.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In the ER, seconds matter when identifying the "Dangerous Tetrad": rigidity, fever, autonomic instability, and altered mentation. This episode breaks down the clinical markers and pathophysiology of these life-threatening syndromes to help clinicians differentiate between NMS and Serotonin Syndrome. A must-listen for healthcare professionals looking to sharpen their diagnostic skills and improve patient outcomes in high-acuity settings.

少見但可能致命的抗精神病藥物惡性症候群（Neuroleptic Malignant Syndrome，簡稱NMS）的臨床表現是如何？ NMS 典型是在暴露於多巴胺阻斷藥物之後出現（最常見是抗精神病藥物，第一代與第二代抗精神病藥物階可能）；從用藥到出現症狀的中位數約 4 天，但也可能快到 1 天內就發作，或延後到 30 天以上才出現。整體病程常在第 2–3 天達到高峰；而在最早期的臨床症狀，常是血壓變動與肌張力增高。 NMS 的核心臨床特徵是：（1）高體溫（嚴重時可到 40°C 以上，大多也會有脫水的症狀）以及（2）自律神經不穩（dysautonomia）、（3）嚴重肌肉僵硬（muscular rigidity）。 ►NMS 的病理機制可能與交感神經—腎上腺素系統過度亢奮有關，這種亢奮會讓肌肉細胞內的鈣離子濃度（intracellular calcium ions）上升，使肌肉張力更高、更僵硬，同時也會出現心跳快、血壓波動、出汗等自律神經症狀。進一步來說，下視丘的多巴胺受體被阻斷，身體的散熱能力會變差；而當掌管運動中樞的基底核系統裡的多巴胺受體被阻斷，會更直接導致明顯的肌肉僵硬（rigidity）。肌肉強直本身會增加產熱，再加上散熱變差，兩者疊加成 NMS最關鍵的臨床指標——高體溫（hyperthermia）。 ►自律神經不穩的表現常包含：心跳加快、血壓快速波動（可高可低）、大量出汗、呼吸變快等；意識狀態改變也很常見，從譫妄、混亂、嗜睡到嚴重時接近僵直症（catatonia）都可能出現。 ►肌肉僵硬檢查時常被形容為「鉛管樣僵硬」（lead-pipe rigidity）：醫師幫病人把手腳關節慢慢彎直時，會覺得從頭到尾都卡卡的、阻力很平均；有時也會出現像巴金森症「齒輪樣」（cogwheel）那樣「一格一格卡住」的感覺。 -最新一集Podcast將分享在新版的《會談地圖》當中，整理自權威醫學期刊 NEJM 關於抗精神病藥物惡性症候群相關的診斷與治療，除了讓大家更加認識抗精神病藥物惡性症候群，也希望將龐雜的醫學資訊拆解，整理出貼近台灣臨床實務的內容！ 本集的Podcast，將會深入的探討： 1️⃣NMS臨床特徵與病理機制：如何將高體溫（Hyperthermia）、自律神經不穩、肌肉僵硬（Rigidity）等病理生理學症狀串聯起來，更全面的理解NMS的病徵及發病原理？ 2️⃣實驗室檢查：會利用甚麼實驗室檢查的數值來診斷NMS？ 3️⃣治療原則： NMS 需要視為重症（ICU 等級）來處理嗎？根據風險大小有哪些治療的方法呢？ 4️⃣預後與醫病溝通：預後也是不可掉以輕心的階段，停藥後的恢復期大約需要多久？有哪些後期併發症是需要留意的呢？ - 如果您對抗精神病藥物惡性症候群的議題充滿興趣，或是想進一步了解更多《新版會談地圖》的內容，歡迎加入

Jak se ženy cítí, když se po setmění pohybují po městě? Dokument Čau šťávo, kam tečeš? přináší osobní svědectví o tom, jaké drobné i zásadní volby činí, aby se cítily bezpečně. Devět z deseti mladých žen se podle výzkumu agentury NMS ocitlo v nepříjemné situaci s muži. Autorka Anna Váchová, studentka sociální antropologie na Masarykově univerzitě v Brně, dává hlas těm, jejichž obavy často zůstávají skryté.

In this episode, Lauren Bookbinder, DVM, DACVIM-LA, joined us to discuss neonatal maladjustment syndrome (NMS) and foal sepsis. She described the causes and clinical signs of NMS, management options, risk of sepsis in these foals, and prognosis. She also discussed other risk factors for foal sepsis, strategies for identifying septic foals, treatment options, and more.This episode of Disease Du Jour is brought to you by Equithrive. Do you have a problem mare? Learn more about the science behind Equithrive Mare Pellets at https://equithrive.com/products/equithrive-mare-pellets.This episode of Disease Du Jour is brought to you by Equithrive.Use promo code DUJOUR to get 20% off your first order, plus free shipping at Equithrive.com.GUESTS AND LINKS - EPISODE 177:Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Dr. Lauren BookbinderPodcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Equithrive.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

In this episode, Lauren Bookbinder, DVM, DACVIM-LA, joined us to discuss neonatal maladjustment syndrome (NMS) and foal sepsis. She described the causes and clinical signs of NMS, management options, risk of sepsis in these foals, and prognosis. She also discussed other risk factors for foal sepsis, strategies for identifying septic foals, treatment options, and more.This episode of Disease Du Jour is brought to you by Equithrive. Do you have a problem mare? Learn more about the science behind Equithrive Mare Pellets at https://equithrive.com/products/equithrive-mare-pellets.This episode of Disease Du Jour is brought to you by Equithrive.Use promo code DUJOUR to get 20% off your first order, plus free shipping at Equithrive.com.GUESTS AND LINKS - EPISODE 177:Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)Guest: Dr. Lauren BookbinderPodcast Website: Disease Du JourThis episode of Disease Du Jour podcast is brought to you by Equithrive.Connect with the Host: Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (CSisson@equinenetwork.com)

Čo hovoria preferencie o našej politike? Zdá sa, že namiesto veľkých posunov vidíme skôr presuny medzi blokmi. Smer ja ako-tak stabilný, opozičný líder klesá, no rastú extrémisti aj Matovičovo hnutie. Do toho na Slovensku udrela ekonomická kríza, ktorú sa vláda snaží prekryť aj kauzou s faktúrami. Ako sa teda momentálne darí politickým stranám, prečo niektoré rastú a iné strácajú a aké to môže mať dôsledky? Tomáš Prokopčák sa v podcaste Dobré ráno pýta politického analytika Mikuláša Hanesa z NMS. Zdroj zvukov: TASR Odporúčanie Mojím dnešným odporúčaním je skvelý seriál Shrinking na Apple TV. Je to vtipné, je to smutné, je to láskavé a z celej tejto série o terapii, vzťahoch a prežívaní straty ide predovšetkým ľudskosť. Skúste. – Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifingSee omnystudio.com/listener for privacy information.

Hnutí Naše Česko vyrazilo do českého politického dostihu opravdu zostra. V průzkumu NMS, což je vůbec první průzkum, který novou formaci jihočeského hejtmana Martina Kuby změřil, dosáhlo bezmála pěti procent, což je hranice pro vstup do Poslanecké sněmovny.

Hnutí Naše Česko vyrazilo do českého politického dostihu opravdu zostra. V průzkumu NMS, což je vůbec první průzkum, který novou formaci jihočeského hejtmana Martina Kuby změřil, dosáhlo bezmála pěti procent, což je hranice pro vstup do Poslanecké sněmovny.Všechny díly podcastu Názory a argumenty můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Episode 210: Heat Stroke BasicsWritten by Jacob Dunn, MS4, American University of the Caribbean. Edits and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice. Definition:Heat stroke represents the most severe form of heat-related illness, characterized by a core body temperature exceeding 40°C (104°F) accompanied by central nervous system (CNS) dysfunction. Arreaza: Key element is the body temperature and altered mental status. Jacob: This life-threatening condition arises from the body's failure to dissipate heat effectively, often in the context of excessive environmental heat load or strenuous physical activity. Arreaza: You mentioned, it is a spectrum. What is the difference between heat exhaustion and heat stroke? Jacob: Unlike milder heat illnesses such as heat exhaustion, heat stroke involves multisystem organ dysfunction driven by direct thermal injury, systemic inflammation, and cytokine release. You can think of it as the body's thermostat breaking under extreme stress — leading to rapid, cascading failures if not addressed immediately. Arreaza: Tell us what you found out about the pathophysiology of heat stroke?Jacob: Pathophysiology: Under normal conditions, the body keeps its core temperature tightly controlled through sweating, vasodilation of skin blood vessels, and behavioral responses like seeking shade or drinking water. But in extreme heat or prolonged exertion, those mechanisms get overwhelmed.Once core temperature rises above about 40°C (104°F), the hypothalamus—the brain's thermostat—can't keep up. The body shifts from controlled thermoregulation to uncontrolled, passive heating. Heat stroke isn't just someone getting too hot—it's a full-blown failure of the body's heat-regulating system. Arreaza: So, it's interesting. the cell functions get affected at this point, several dangerous processes start happening at the same time.Jacob: Yes: Cellular Heat InjuryHigh temperatures disrupt proteins, enzymes, and cell membranes. Mitochondria start to fail, ATP production drops, and cells become leaky. This leads to direct tissue injury in vital organs like the brain, liver, kidneys, and heart.Arreaza: Yikes. Cytokines play a big role in the pathophysiology of heat stroke too. Jacob: Systemic Inflammatory ResponseHeat damages the gut barrier, allowing endotoxins to enter the bloodstream. This triggers a massive cytokine release—similar to sepsis. The result is widespread inflammation, endothelial injury, and microvascular collapse.Arreaza: What other systems are affected?Coagulation AbnormalitiesEndothelial damage activates the clotting cascade. Patients may develop a DIC-like picture: microthrombi forming in some areas while clotting factors get consumed in others. This contributes to organ dysfunction and bleeding.Circulatory CollapseAs the body shunts blood to the skin for cooling, perfusion to vital organs drops. Combine that with dehydration from sweating and fluid loss, and you get hypotension, decreased cardiac output, and worsening ischemia.Arreaza: And one of the key features is neurologic dysfunction.Jacob: Neurologic DysfunctionThe brain is extremely sensitive to heat. Encephalopathy, confusion, seizures, and coma occur because neurons malfunction at high temperatures. This is why altered mental status is the hallmark of true heat stroke.Arreaza: Cell injury, inflammation, coagulopathy, circulatory collapse and neurologic dysfunction. Jacob: Ultimately, heat stroke is a multisystem catastrophic event—a combination of thermal injury, inflammatory storm, coagulopathy, and circulatory collapse. Without rapid cooling and aggressive supportive care, these processes spiral into irreversible organ failure.Background and Types:Arreaza: Heat stroke is part of a spectrum of heat-related disorders—it is a true medical emergency. Mortality rate reaches 30%, even with optimal treatment. This mortality correlates directly with the duration of core hyperthermia. I'm reminded of the first time I heard about heat stroke in a baby who was left inside a car in the summer 2005. Jacob: There are two primary types: -nonexertional (classic) heat stroke, which develops insidiously over days and predominantly affects vulnerable populations like children, the elderly, and those with chronic illnesses during heat waves; -exertional heat stroke, which strikes rapidly in young, otherwise healthy individuals, often during intense exercise in hot, humid conditions. Arreaza: In our community, farm workers are especially at risk of heat stroke, but any person living in the Central Valley is basically at risk.Jacob: Risk factors amplify vulnerability across both types, including dehydration, cardiovascular disease, medications that impair sweating (e.g., anticholinergics), and acclimatization deficits. Notably, anhidrosis (lack of sweating) is common but not required for diagnosis. Hot, dry skin can signal the shift from heat exhaustion to stroke. Arreaza: What other conditions look like heat stroke?Differential Diagnosis:Jacob: Presenting with altered mental status and hyperthermia, heat stroke demands a broad differential to avoid missing mimics. -Environmental: heat exhaustion, syncope, or cramps. -Infectious etiologies like sepsis or meningitis must be ruled out. -Endocrine emergencies such as thyroid storm, pheochromocytoma, or diabetic ketoacidosis (DKA) can overlap. -Neurologic insults include cerebrovascular accident (CVA), hypothalamic lesions (bleeding or infarct), or status epilepticus. -Toxicologic culprits are plentiful—sympathomimetic or anticholinergic toxidromes, salicylate poisoning, serotonin syndrome, malignant hyperthermia, neuroleptic malignant syndrome (NMS), or even alcohol/benzodiazepine withdrawal. When it comes to differentials, it is always best to cast a wide net and think about what we could be missing if this is not heat stroke. Arreaza: Let's say we have a patient with hyperthermia and we have to assess him in the ER. What should we do to diagnose it?Jacob: Workup:Diagnosis is primarily clinical, hinging on documented hyperthermia (>40°C) plus CNS changes (e.g., confusion, delirium, seizures, coma) in a hot environment. Arreaza: No single lab confirms it, but targeted testing allows us to detect complications and rule out alternative diagnosis. Jacob: -Start with ECG to assess for dysrhythmias or ischemic changes (sinus tachycardia is classic; ST depressions or T-wave inversions may hint at myocardial strain). -Labs include complete blood count (CBC), comprehensive metabolic panel (electrolytes, renal function, liver enzymes), glucose, arterial blood gas, lactate (elevated in shock), coagulation studies (for disseminated intravascular coagulation, or DIC), creatine kinase (CK) and myoglobin (for rhabdomyolysis), and urinalysis. Toxicology screen if history suggests. Arreaza: I can imagine doing all this while trying to cool down the patient. What about imaging?-Imaging: chest X-ray for pulmonary issues, non-contrast head CT if neurologic concerns suggest edema or bleed (consider lumbar puncture if infection suspected). It is important to note that continuous core temperature monitoring—via rectal, esophageal, or bladder probe—is essential, not just peripheral skin checks. Arreaza: TreatmentManagement:Time is tissue here—initiate cooling en route, if possible, as delays skyrocket morbidity. ABCs first: secure airway (intubate if needed, favoring rocuronium over succinylcholine to avoid hyperkalemia risk), support breathing, and stabilize circulation. -Remove the patient from the heat source, strip clothing, and launch aggressive cooling to target 38-39°C (102-102°F) before halting to prevent rebound hypothermia. -For exertional cases, ice-water immersion reigns supreme—it's the fastest method, with immersion in cold water resulting in near-100% survival if started within 30 minutes. -Nonexertional benefits from evaporative cooling: mist with tepid water (15-25°C) plus fans for convective airflow. -Adjuncts include ice packs to neck, axillae, and groin; -room-temperature IV fluids (avoid cold initially to prevent shivering); -refractory cases, invasive options like peritoneal lavage, endovascular cooling catheters, or even ECMO. -Fluid resuscitation with lactated Ringer's or normal saline (250-500 mL boluses) protects kidneys and counters rhabdomyolysis—aim for urine output of 2-3 mL/kg/hour. Arreaza: What about medications?Jacob: Benzodiazepines (e.g., lorazepam) control agitation, seizures, or shivering; propofol or fentanyl if intubated. Avoid antipyretics like acetaminophen. For intubation, etomidate or ketamine as induction agents. Hypotension often resolves with cooling and fluids; if not, use dopamine or dobutamine over norepinephrine to avoid vasoconstriction. Jacob: What IV fluid is recommended/best for patients with heat stroke?Both lactated Ringer's solution and normal saline are recommended as initial IV fluids for rehydration, but balanced crystalloids such as LR are increasingly favored due to their lower risk of hyperchloremic metabolic acidosis and AKI. However, direct evidence comparing the two specifically in the setting of heat stroke is limited. Arreaza: Are cold IV fluids better/preferred over room temperature fluids?Cold IV fluids are recommended as an adjunctive therapy to help lower core temperature in heat stroke, but they should not delay or replace primary cooling methods such as cold-water immersion. Cold IV fluids can decrease core temperature more rapidly than room temperature fluids. For example, 30mL/kg bolus of chilled isotonic fluids at 4 degrees Celsius over 30 minutes can decrease core temperature by about 1 degree Celsius, compared to 0.5 degree Celsius with room temperature fluids. Arreaza: Getting cold IV sounds uncomfortable but necessary for those patients. Our favorite topic.Screening and Prevention:-Heat stroke prevention focuses on public health and individual awareness rather than routine testing. -High-risk groups—elderly, children, athletes, laborers, or those on impairing meds—should acclimatize gradually (7-14 days), hydrate preemptively (electrolyte solutions over plain water), and monitor temperature in exertional settings. -Communities during heat waves need cooling centers and alerts. -For clinicians, educate patients with CVD or obesity about early signs like dizziness or nausea. -No formal "screening" exists, but vigilance in EDs during summer surges saves lives. -Arreaza: I think awareness is a key element in prevention, so education of the public through traditional media like TV, and even social media can contribute to the prevention of this catastrophic condition.Jacob: Ya so heat stroke is something that should be on every physician's radar in the central valley especially in the summer time given the hot temperatures. Rapid recognition is key. Arreaza: Thanks, Jacob for this topic, and until next time, this is Dr. Arreaza, signing off.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! References:Gaudio FG, Grissom CK. Cooling Methods in Heat Stroke. J Emerg Med. 2016 Apr;50(4):607-16. doi: 10.1016/j.jemermed.2015.09.014. Epub 2015 Oct 31. PMID: 26525947. https://pubmed.ncbi.nlm.nih.gov/26525947/.Platt, M. A., & LoVecchio, F. (n.d.). Nonexertional classic heat stroke in adults. In UpToDate. Retrieved September 7, 2025, from https://www.uptodate.com/contents/nonexertional-classic-heat-stroke-in-adults. (Key addition: Emphasizes insidious onset in at-risk populations and the role of urban heat islands in exacerbating classic cases.) Heat Stroke. WikEM. Retrieved December 3, 2025, from https://wikem.org/wiki/Heat_stroke. (Key additions: Details on cooling rates for immersion therapy, confirmation that anhidrosis is not diagnostic, and fluid titration to urine output for rhabdomyolysis prevention.)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

Tři čtvrtiny lidí by si přáli, aby Andrej Babiš (ANO) veřejně představil řešení svého střetu zájmů, jak požaduje prezident Petr Pavel, zjistil průzkum pro Český rozhlas od agentury NMS. „Prezident se nechce stát spolupachatelem porušení právního řádu,“ říká v pořadu Pro a proti poslankyně Pirátské strany Kateřina Stojanová. „Nemůže podmiňovat jmenování premiéra velmi extenzivním výkladem zákona,“ nesouhlasí poslanec hnutí ANO Radek Vondráček.Všechny díly podcastu Pro a proti můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

In Episode 30 of Queer Storytime, Stevie sits down with Valentina “Vale” Mendoza — a Chicana trans woman, former Wall Street transactional attorney, founder of MeVale, P.C., and a 2026 grassroots congressional candidate running in New Jersey's 7th District. With a bold platform rooted in economic, racial, and social justice, Vale represents a new generation of political leadership: unapologetically queer, deeply community-grounded, and unwilling to compromise people's humanity for political convenience.Stevie opens the episode with a grounding invitation — a reminder to breathe, to reset, and to reconnect with our bodies in a moment when the nation is gripped by fear, fascism, and political instability. From there, this conversation moves between the personal and the political with intention: Vale speaks candidly about growing up the daughter of working-class immigrants, navigating transition, overcoming corporate disillusionment, and finding her purpose through survival, recovery, and community.Together, Stevie and Vale unpack major questions facing the country today:What does liberation actually mean — spiritually, politically, and materially?Is the U.S. Constitution a living document meant to evolve?How do we move people out of fight-or-flight long enough to talk about policy?Where has the Democratic Party abandoned its values — and why is performative allyship a threat?Why is democratic socialism resonating with new generations of voters?How can economic, racial, and social justice be pursued as interconnected goals?What qualifications should be required for elected office?What does genuine representation look like for queer, trans, disabled, working-class, and immigrant communities?Vale brings forward a vision for systemic change: worker empowerment, class consciousness, dismantling billionaire influence, addressing disability inequities, and building economic systems that honor human dignity rather than extract from it. She also offers sharp reflections on the political center drifting rightward — and why rhetoric from so-called allies harms vulnerable communities as much as overt hate.As the episode moves into its reflective closing, Vale and Stevie explore purpose, identity, joy, community, and the spiritual dimensions of political work. Vale shares a message for queer and trans youth, a warning for legislators targeting LGBTQ+ lives, and a truth many of us know intimately: trans people become experts at transformation because our survival demands it.This episode is essential listening for anyone navigating despair in today's political climate — and for those seeking grounded, intersectional, justice-driven leadership directly from the communities most impacted.

Welcome, dolls, gays, & theys; thank you for tuning in to Queer Story Time. In this episode, Stevie sits down with Dakarai Larriett, a proud son of Alabama, entrepreneur, community volunteer, and U.S. Senate candidate whose campaign was born from a traumatic false arrest. Drawing from a lifetime of lived experience, growing up a Jehovah's Witness, navigating body dysphoria as a teen with gynecomastia, and building a career before returning home. Dakarai shares how his journey through faith, shame, and resilience shaped his mission to fight for justice, healthcare, and dignity for marginalized communities.Together, Stevie and Dakarai explore how personal harm transforms into political action. Dakarai recounts the racial and homophobic profiling that led to his arrest and how that experience inspired his Motorist Bill of Rights, calling for greater transparency, access to bodycam footage, and fair policing. The conversation also dives into Alabama's pressing issues from rural hospital closures and maternal health disparities to education, economic opportunity, and voter suppression, all through the lens of lived experience.This episode blends intimate truth-telling with bold policy vision, asking what it truly takes to represent people who've been pushed to the margins, and how compassion, courage, and representation can change the system from within.What you'll hear in this episodeDakarai's childhood in Alabama and faith journey away from Jehovah's Witnesses toward a welcoming UMC community.The physical and emotional impact of gynecomastia and why body-related shame matters to public health conversations.The false arrest: dashcam/bodycam evidence, dehumanizing language by officers, and the broken accountability system.Why Dakarai turned trauma into activism and a Senate run, and what justice means to him.Concrete policy proposals: Motorist Bill of Rights, healthcare access (Medicare/Medicaid expansion), maternal health, education investment, and voter access.A candid conversation about representation, the politics of the South, and how to build coalitions that protect the most vulnerable.

Mládí vpřed a více žen. Jak se změní Sněmovna? Kdo volil koho? Proč dominoval Babiš? Kvůli čemu vyhořeli komunisté? A kdo to hodil Motoristům? Velká analýza voleb s Terezou Friedrichovou z agentury NMS a Michalem Kormaňákem z Ipsosu. Ptá se Matěj Skalický.

Mládí vpřed a více žen. Jak se změní Sněmovna? Kdo volil koho? Proč dominoval Babiš? Kvůli čemu vyhořeli komunisté? A kdo to hodil Motoristům? Velká analýza voleb s Terezou Friedrichovou z agentury NMS a Michalem Kormaňákem z Ipsosu. Ptá se Matěj Skalický. Všechny díly podcastu Vinohradská 12 můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

In this powerful and deeply moving episode, I'm joined by Renee Thibeau, a devoted mother, passionate advocate, and fierce ally to the transgender community. Renee is the proud mom of three incredible children: her oldest, a 25-year-old cisgender daughter; her 17-year-old son, who is autistic and full of love and light; and her courageous transgender daughter — the reason she has stepped so fully into public advocacy.Renee's journey began when her ten-year-old child shared that she was a girl living in a boy's body and, heartbreakingly, had contemplated ending her own life. Faced with this reality, Renee chose love, acceptance, and action. By affirming her daughter's truth, advocating for her well-being, and surrounding her with support, Renee helped transform despair into hope and fear into thriving.Now, Renee speaks out publicly to share their story — not for recognition, but because she knows the stakes. Every child deserves to be seen and accepted for who they truly are, and every parent has the power to save a life with love. Through her writing, speaking, and tireless advocacy, Renee proves that empathy and understanding are life-saving acts, and that true success is measured not by accolades but by the lives we protect.Together, we dive deep into:The myths and false narratives fueling anti-trans rhetoric in politics and religionRenee's personal journey as a parent and the unconditional love that guided her through her daughter's transitionStories of support, including her late Aunt Sylvia—a nun whose unwavering affirmation reminds us of the true meaning of faithThe dangerous hypocrisy of lawmakers who legislate against the LGBTQ+ community while hiding their own truthsHow complacency and societal blind spots have contributed to the rise of harmful cultural narrativesWhy hormone therapy is reversible, but suicide is not — a stark reality we cannot ignoreWhat it means to raise trans kids with joy, love, and dignity, while preparing them for futures full of hopeRenee shares her heart, her advocacy, and her unapologetic truth, reminding us that being an ally isn't passive — it's about showing up, speaking out, and protecting the most vulnerable among us.This is a deeply moving, fiery, and inspiring conversation you won't want to miss.

0:00 Hey Hey it's MonJay, Scrubbing Bubbles2:52 Intro/Housekeeping6:05 AJ Hidden Gems Video9:06 No Mans Sky Update15:30 Tips, Spooky Season Is On!21:30 Bryans Spooky Season Plans23:45 Tips, State Of Play27:43 Zombie Army VR33:05 Tips, NMS, Aces Of Thunder45:00 More Tips55:45 Games On Sale1:22:45 Tips1:25:30 Four Minute Challenge1:33:15 Tips 1:36:05 Thank You!1:37:05 Outro, AJ Shoutouts1:40:00 Poll Results

0:00 Hey Hey it's WesDay1:13 Intro/Housekeeping4:00 Reviewing Into Black8:13 Tips, NMS, Into Black21:05 NMS Update with PSSR!39:30 Tips, PSSR43:45 Grimlord50:45 Aces Of Thunder New Release Date? 59:05 Tips, Cats1:07:30 Four Minute Challenge1:17:30 Virtual Strangers Upcoming Stuff1:18:40 Thank You! 1:19:56 Outro1:21:25 Flashback Aug 7, 2021

Welcome back to Queer Story Time The Podcast where we honor the lived experiences, wisdom, and resilience of LGBTQ+ individuals across generations. I'm your host, Stevie, and today's episode features a very special guest: Wendy Cole (she/her), a 77-year-old transgender woman whose life and voice are a beacon for so many in our community—especially those navigating transition later in life.Wendy is a transition mentor, public speaker, podcast host, and truth-teller whose work is rooted in compassion, candor, and fierce advocacy. After beginning her transition in her late 60s, Wendy has made it her mission to support and guide other trans people through their own journeys—offering not only practical tools and emotional accountability, but also the kind of lived wisdom that only comes from doing the hard work of becoming your full self.Wendy co-hosts Demystifying The Transgender Journey Podcast and is a visible presence across social media and public speaking platforms, using her voice to humanize trans experiences, challenge harmful narratives, and affirm that authenticity has no expiration date. Whether she's speaking to a room full of allies, mentoring one-on-one, or pushing back against legislative attacks, Wendy's message is clear: we've always been here, and we are not going back into hiding.

In this deeply moving Pride Month episode of Queer Storytime, we center community voices and the power of storytelling to uplift, reflect, and affirm our shared humanity. Host Stevie, shares five personal messages from queer and trans individuals, and their loved ones. Highlighting the resilience, growth, and connection that define our community. 

Fluphenazine is a high-potency typical antipsychotic that primarily acts as a dopamine D2 receptor antagonist in the mesolimbic pathway, reducing positive symptoms of schizophrenia. Extrapyramidal symptoms (EPS), such as dystonia, akathisia, and parkinsonism, are common due to potent D2 blockade in the nigrostriatal pathway. Neuroleptic malignant syndrome (NMS), though rare, is a life-threatening adverse effect characterized by rigidity, hyperthermia, altered mental status, and autonomic instability. CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase fluphenazine plasma concentrations, potentially raising the risk of toxicity and side effects. Concomitant use of fluphenazine with CNS depressants (e.g., alcohol, benzodiazepines) can enhance sedation and respiratory depression.

Happy Pride to all the dolls, gays, theys, and beyond! We're celebrating two major milestones in this episode: Pride 2025 coincides with our 25th episode! Host Stevie Inghram takes the mic solo in this heartfelt reflection, offering eight profound truths learned from over a year of powerful conversations with queer and trans guests from around the world.Based on a widely loved blog post from her new site www.futuredrstevie.com, this episode explores the resilience, wisdom, and beauty within the LGBTQIA+ community and the healing power of storytelling, science, and chosen family.From our century old fight for survival and the impact of white supremacy on queer existence to the truth that not all queer people can - or should - come out, Stevie's words are an invitation to deepen our understanding, reframe pride, and commit to a shared vision of healing and liberation.✨ Key themes include:Why queer and trans people simply want to grow old in peaceThe myth that politicians can erase our existenceHow community transforms traumaWhat respect actually looks likeThe importance of allowing queer folks to choose not to come outWhy your own inner work supports the liberation of othersThe universal possibility of embodying your true self at any age

Pre väčšinu Slovákov je rodina ešte stále hlavným zdrojom bezpečia, blízkosti i dôvery. Tento základný pocit však dnes ohrozujú obavy z nedostatku peňazí, ale aj politika, ktorá dokáže rodiny generačne štiepiť. Zásadnou obavou je i strach, že sa nedokážeme postarať o nemohúceho príbuzného. Pre väčšinu Slovákov je doteraz rodina hlavným zdrojom bezpečia, blízkosti i dôvery. Aktuálne však existujú minimálne dva, presnejšie tri kľúčové faktory, ktorý tento pocit silne nahlodávajú. Okrem už tradičného problému nedostatku financií, je to aktuálne tak silná polarizácia na našej politickej scéne, že svojou intenzitou zasahuje už aj do úzkych rodinných väzieb. Nemenej prekvapivé môžu byť aj naše obavy o to, ako sa dokážeme postarať o rodinných príslušníkov, ktorí majú nejaký vážny zdravotný problém či trpia nejakým zdravotným znevýhodnením. To toľko proklamované bezpečie rodinného krbu - kam sa však väčšina z nás tradične utieka, tak môže byť dnes oveľa krehkejšie, než ako by sme chceli. To všetko vyplýva z prieskumu realizovaného agentúrou NMS pre finančný dom Uniqa.Väčšia časť našej populácie dokáže mať (i v rámci rodiny) nejaký zhodný názor, to čo to štiepi a polarizuje sú vyjadrenia a činy politikov, ktorí sa medzi sebou radi vymedzujú, hovorí Michal Mislovič z agentúry NMS.A ešte jedna zaujímavosť. Slováci vidia rodinu hlavne tam, kde sú deti Každé spolužitie s deťmi je väčšinovo označované za rodinu a to bez ohľadu na to, akí dospelí sa o deti starajú.O čom tieto naše obavy vypovedajú a sú i dôsledkom zlyhávajúceho štátu v jeho sociálnych záväzkoch či nedostatku empatie a sebastrednosti našich politických elít? Čo s tým vieme urobiť a aký dosah to má na súdržnosť celej našej spoločnosti?No a napokon, nakoľko sme ešte stále tradičnou spoločnosťou koreniacou vo vzorcoch z minulého či dokonca predminulého storočia?Ráno Nahlas, dnes s analytikom Michalom Mislovičom z výskumnej agentúry NMS. Pekný deň a pokoj v duši praje Braňo Dobšinský.

„To není žádná demokracie,“ prohlásil Andrej Babiš v rozhovoru pro Deník.cz v reakci na radikální celní politiku Donalda Trumpa. Také dodal, že má s americkým prezidentem společnou hlavně červenou barvu kampaně. Přitom ještě v listopadu minulého roku prohlásil, že de facto mají totožné programy. „Jsem přesvědčen, že Donald Trump je nejlepším řešením pro Evropu a také pro celý svět,“ pronesl na CNN Prima News.  Před čtrnácti dny ovšem zveřejnila agentura NMS průzkum, z něhož vyplynulo, že Trumpovu politiku v Česku podporuje jen 20 procent lidí a celých 40 procent jako hlavního představitele trumpismu u nás vidí Andreje Babiše. Začal velký obrat a předstírání, že s Trumpem nemá on ani hnutí ANO vlastně nic společného.  Zároveň zaregistroval, že mu volební preference nerostou, takže začala zákulisní jednání se Socdem o účasti některých špičkových politiků na kandidátce hnutí ANO. Babiš na to jde tak, že jakoby nechává jednání na krajských organizacích, aby pak mohl říct: je to rozhodnutí regionů. Jednání však stále ještě nejsou u konce, protože Socdem chce vytvořit s ANO formální koalici.  Co může být černou labutí říjnových sněmovních voleb? Jak si Lubomír Zaorálek představuje akciový trh? A co je smyslem Trumpovy těkavé ekonomické politiky?

Today we're going to break down three life-threatening syndromes that every CRNA, anesthesia provider, and healthcare professional should know: Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS), and Malignant Hyperthermia (MH). Though these conditions are rare, their symptoms often overlap—making quick, accurate diagnosis and intervention critical. Garry and Terry take a deep dive into the causes, symptoms, physiology, and treatment protocols for each condition, while also sprinkling in their signature humor and real-world insights. Here's some of what we discuss in this episode:

According to the latest data from research agency NMS, 16% of women in Slovakia suffer from period poverty. This term is desribed as lack of access to sanitary and menstrual products. We talked to Natália Blahová, a representative from the initiative Dôstojná menštruácia, who explains what this alarming problem means from women and how to fight it.

In this powerful episode of Queer Storytime, we dive deep into the urgent and historical topic of mutual aid within the LGBTQIA+ community. From the Stonewall era to the HIV/AIDS crisis and today's escalating attacks on gender and sexually affirming health care, mutual aid has been a lifeline for queer and trans folks.Stevie lays out the distinction between charity and solidarity, highlighting why institutional approaches often fall short. As mainstream LGBTQIA+ organizations amass wealth, the most vulnerable in our community — Black and Brown trans folks, unhoused queer youth, disabled queer individuals, and those living under oppressive legal systems — are left behind.This episode announces a groundbreaking new initiative: A Mutual Aid Collective for LGBTQIA+ Health & Wellbeing. This network will provide access to holistic health resources, guidance, and sliding-scale services for queer and trans individuals, especially those living in states where affirming healthcare is under attack.Listen now to learn about our community's resilience, why we need to reclaim the true spirit of mutual aid, and how you can support this collective effort. Remember, our survival is the ultimate act of resistance.Key Topics Covered:The historical precedent of mutual aid within the LGBTQIA+ community.The distinction between charity and solidarity.Criticism of mainstream LGBTQIA+ organizations hoarding wealth.Introduction of the Mutual Aid Collective for LGBTQIA+ Health & Wellbeing.How listeners can support or access this new initiative.Calls for community-based, nonhierarchical, direct aid over bureaucratic charity models.Call to Action:✨ Get Involved: If you're in a position to contribute financially, share skills, or simply spread the word, support the Mutual Aid Collective by visiting here - https://opencollective.com/queer-trans-thriving 

Now that the dust has settled it turns out that Assassin’s Creed Shadows is a really really good game. We also talk about some NMS new update news, Dun Awakening pricing, and a bit of WoW Hardcord DDOS drama. That and more on this episode of the New Overlords Podcast with Sema and @MaxTheGrey. MP3 … New Overlords Podcast 552: Assassin’s Creed Shadows Read More » The post New Overlords Podcast 552: Assassin's Creed Shadows first appeared on NEW OVERLORDS.

This week we talk about the NMS expedition and the new planet tech Hello Games has added. Then we catch up on what’s know and not known about Light No Fire, how the NMS stuff figures in, and what we hope for. That and more on this episode of the New Overlords Podcast with Sema … New Overlords Podcast 547: No Man’s Sky and Light No Fire Read More » The post New Overlords Podcast 547: No Man's Sky and Light No Fire first appeared on NEW OVERLORDS.